Hookipa Pharma (NASDAQ:HOOK) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Hookipa Pharma (NASDAQ:HOOK) from a buy rating to a hold rating in a research note released on Saturday, Zacks.com reports.

According to Zacks, “HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company. It is engaged in developing a class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform which is designed to reprogram the body’s immune system. HOOKIPA Pharma Inc. is based in New York, United States. “

A number of other brokerages also recently weighed in on HOOK. Leerink Swann assumed coverage on Hookipa Pharma in a report on Monday, May 13th. They set an outperform rating and a $20.00 price target on the stock. Royal Bank of Canada reiterated a buy rating and set a $23.00 price target on shares of Hookipa Pharma in a report on Wednesday, August 14th. Svb Leerink assumed coverage on Hookipa Pharma in a report on Monday, May 13th. They set an outperform rating and a $20.00 price target on the stock. Finally, Bank of America started coverage on Hookipa Pharma in a report on Monday, May 13th. They set a buy rating and a $17.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $17.55.

Shares of HOOK stock opened at $7.30 on Friday. Hookipa Pharma has a 1-year low of $6.06 and a 1-year high of $14.76. The company has a current ratio of 8.69, a quick ratio of 5.62 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $7.02.

Hookipa Pharma (NASDAQ:HOOK) last issued its quarterly earnings results on Monday, May 20th. The company reported ($9.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($8.85). The firm had revenue of $2.24 million during the quarter, compared to analyst estimates of $0.50 million. On average, equities research analysts anticipate that Hookipa Pharma will post -2.02 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of HOOK. Hillhouse Capital Advisors LTD. purchased a new stake in Hookipa Pharma during the 2nd quarter worth approximately $1,923,000. Hillhouse Capital Management LTD. purchased a new stake in Hookipa Pharma during the 2nd quarter worth approximately $4,425,000. Morgan Stanley purchased a new stake in Hookipa Pharma during the 2nd quarter worth approximately $99,000. Samsara BioCapital LLC purchased a new stake in Hookipa Pharma during the 2nd quarter worth approximately $3,569,000. Finally, Vanguard Group Inc. purchased a new stake in Hookipa Pharma during the 2nd quarter worth approximately $538,000. Hedge funds and other institutional investors own 9.48% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Read More: Put Option

Get a free copy of the Zacks research report on Hookipa Pharma (HOOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.